Philip Joens When word leaked that the Food and Drug Administration declined to approve a Novartis biosimilar of an Amgen drug July 19, there was silence from the pharmaceuticals. But when regulators like the FDA or the European Medicines Agency approve new drugs, the news is celebrated by companies as if fireworks should explode and…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
